

ROCKPOINTE, INC.
SCHEDULE OF PAYMENTS
01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
AstraZeneca	Choosing Cholesterol Lowering Therapy: Evidence Supporting Efficacy and Safety	CME	10/18/2006	150,000.00	
AstraZeneca	Managing Type 2 Diabetes Across the Globe	CME	12/18/2006	114,439.20	
AstraZeneca	Choosing Cholesterol Lowering Therapy: Evidence Supporting Efficacy and Safety	CME	12/18/2006	140,000.00	
AstraZeneca	Total 2006 AstraZeneca Payments				404,439.20
GE Healthcare	Echocardiography Contrast Coalition to Optimize Diagnostic Efficiency	CME	04/06/2006	14,000.50	
GE Healthcare	Total 2006 GE Healthcare Payments				14,000.50
Medtronic	Profiling the Coronary Stent Patient: Improving Understanding and Clinical Decision-Making	CME	11/07/2006	123,935.80	
Medtronic	Profiling the Coronary Stent Patient: Improving Understanding and Clinical Decision-Making	CME	11/09/2006	92,951.85	
Medtronic	Total 2006 Medtronic Payments				216,887.65
Merck	Herpes Zoster and Post Herpetic Neuralgia	CME	01/03/2006	291,000.00	
Merck	The Puzzle of Cardiovascular Disease and Its Comorbidities: Are we Asking the Right Question?	CME	01/03/2006	97,500.00	
Merck	On Thin Ice: New Perspectives on Assessing Osteoporotic Risk and Insights into Treatment Strategies	CME	03/27/2006	150,000.00	
Merck	The Dilemma of Managing Cardiovascular Disease and Metabolic Risk	CME	04/06/2006	245,000.00	
Merck	Herpes Zoster and Post Herpetic Neuralgia	CME	04/13/2006	77,000.00	
Merck	The Face of Osteoporosis: The Complete Physician's Guide to Bone Health	CME	04/13/2006	50,000.00	
Merck	The Dilemma of Managing Cardiovascular Disease and Metabolic Risk	CME	05/09/2006	105,000.00	
Merck	Herpes Zoster: Current and Emerging Strategies	CME	05/09/2006	70,748.75	
Merck	Herpes Zoster and Post Herpetic Neuralgia: New Solutions for Prevention	CME	05/09/2006	75,226.25	
Merck	Clinical Perspectives for Nurse Practitioners: Advances in the Prevention of HPV and Cervical Cancer	CME	05/17/2006	141,497.50	
Merck	On Thin Ice: New Perspectives on Assessing Osteoporotic Risk and Insights into Treatment Strategies	CME	05/22/2006	250,000.00	
Merck	The Face of Osteoporosis: The Complete Physician's Guide to Bone Health	CME	05/22/2006	300,000.00	
Merck	Advances in The Prevention of Herpes Zoster	CME	06/07/2006	70,748.75	
Merck	Herpes Zoster and Post Herpetic Neuralgia: New Solutions for Prevention	CME	06/07/2006	75,226.25	
Merck	Treating the Early Stage Breast Cancer Patient	CME	07/10/2006	250,000.00	
Merck	New Advances in the Prevention of HPV and Cervical Cancer	CME	08/01/2006	149,968.00	
Merck	On Thin Ice: New Perspectives on Assessing Osteoporotic Risk and Insights into Treatment Strategies	CME	09/15/2006	117,371.50	
Merck	Herpes Zoster: Current and Emerging Strategies	CME	10/30/2006	249,804.00	
Merck	The Face of Osteoporosis: The Complete Physician's Guide to Bone Health	CME	11/16/2006	142,319.65	
Merck	Total 2006 Merck Payments				2,908,410.65
Merck Schering Plough	Making the Case for Greater CHD Risk Reduction	CME	09/21/2006	150,049.20	
Merck Schering Plough	Total 2006 Merck Schering Plough Payments				150,049.20
Pfizer	Smoking Cessation Working Group: Best Practices Exchange and Dissemination	CME	07/17/2006	175,450.00	
Pfizer	Total 2006 Pfizer Payments				175,450.00
Pharmion	MDS In Focus	CME	07/31/2006	96,067.00	
Pharmion	MDS In Focus	CME	10/26/2006	59,811.00	
Pharmion	Total 2006 Pharmion Payments				155,878.00
P&G Pharmaceuticals	Preventing CABG-Related Events	CME	03/07/2006	38,750.00	
P&G Pharmaceuticals	Total 2006 P&G Pharmaceuticals Payments				38,750.00
QLT, Inc.	Catheter-Based Treatments in Prostate Disease	CME	02/27/2006	5,737.50	
QLT, Inc.	Catheter-Based Treatments in Prostate Disease	CME	03/07/2006	5,737.50	
QLT, Inc.	Total 2006 QLT, Inc. Payments				11,475.00
TEVA Neuroscience	Multiple Sclerosis: Understanding Disease and Therapies	CME	01/19/2006	47,525.00	

ROCKPOINTE, INC.
 SCHEDULE OF PAYMENTS
 01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
TEVA Neuroscience	Multiple Sclerosis Therapies: Unique Mechanisms of Action	CME	02/03/2006	10,000.00	
TEVA Neuroscience	Multiple Sclerosis:Understanding Disease and Therapies	CME	02/17/2006	43,625.00	
TEVA Neuroscience	Multiple Sclerosis:Understanding Disease and Therapies	CME	03/23/2006	8,575.00	
TEVA Neuroscience	Multiple Sclerosis Therapies: Unique Mechanisms of Action	CME	03/23/2006	16,272.00	
TEVA Neuroscience	Multiple Sclerosis Therapies: Unique Mechanisms of Action	CME	06/05/2006	7,775.00	
TEVA Neuroscience	Multiple Sclerosis:Understanding Disease and Therapies	CME	12/04/2006	575.00	
TEVA Neuroscience	Total 2006 TEVA Payments				134,347.00

ROCKPOINTE, INC.
SCHEDULE OF PAYMENTS
01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
AstraZeneca	Addressing Cholesterol Treatment Gaps: Improving Clinical Practice to Safely and Effectively Get to Goal	CME	03/02/2007	206,662.00	
AstraZeneca	Managing Type 2 Diabetes Across the Globe	CME	03/19/2007	28,609.80	
AstraZeneca	Addressing Cholesterol Treatment Gaps: Improving Clinical Practice to Safely and Effectively Get to Goal	CME	04/02/2007	50,000.00	
AstraZeneca	Addressing Cholesterol Treatment Gaps: Improving Clinical Practice to Safely and Effectively Get to Goal	CME	04/13/2007	75,000.00	
AstraZeneca	Choosing Cholesterol Lowering Therapy: Evidence Supporting Efficacy and Safety	CME	10/17/2007	34,472.00	
AstraZeneca	Addressing Cholesterol Treatment Gaps: Improving Clinical Practice to Safely and Effectively Get to Goal	CME	10/17/2007	103,331.00	
AstraZeneca	Addressing Cholesterol Treatment Gaps: Can We Safely & Effectively Get to Goal?	CME	11/13/2007	39,355.00	
AstraZeneca	Total 2007 AstraZeneca Payments				537,429.80
Bristol-Myers-Squibb	A Practical Guide to Contrast Echocardiography: Meeting the Needs of Our Patients	CME	09/25/2007	183,365.00	
Bristol-Myers-Squibb	Total 2007 Bristol-Myers-Squibb Payments				183,365.00
Daiichi Sankyo	CVD Risk Management in Perspective: Therapies to Avoid the Consequences of Hypertension	CME	01/04/2007	147,411.00	
Daiichi Sankyo	Greater Blood Pressure Control	CME	02/08/2007	349,428.00	
Daiichi Sankyo	CVD Risk Management in Perspective: Therapies to Avoid the Consequences of Hypertension	CME	03/19/2007	147,411.00	
Daiichi Sankyo	Hypertension Disparities: Implications for Treatment	CME	04/24/2007	68,020.00	
Daiichi Sankyo	Total 2007 Daiichi Sankyo Payments				712,270.00
Eli Lilly	Time is Muscle: STEMI Strategies to Match Patients with Therapy	CME	01/17/2007	107,750.00	
Eli Lilly	Optimizing Chemotherapy Outcomes	CME	01/30/2007	116,992.50	
Eli Lilly	Time is Muscle: STEMI Strategies to Match Patients with Therapy	CME	03/19/2007	107,750.00	
Eli Lilly	Optimizing Chemotherapy Outcomes	CME	04/17/2007	116,992.50	
Eli Lilly	New Patient Care for STEMI	CME	08/16/2007	139,792.50	
Eli Lilly	New Patient Care for STEMI	CME	10/08/2007	69,896.25	
Eli Lilly	Total 2007 Eli Lilly Payments				659,173.75
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	01/04/2007	154,919.75	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	01/04/2007	92,951.85	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	04/02/2007	100,000.00	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	04/11/2007	100,000.00	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	04/11/2007	100,000.00	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	04/24/2007	100,000.00	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	05/16/2007	54,919.75	
Medtronic	Controversies in Stent Therapy: Clarifying Safety and Charting the Course Ahead	CME	05/16/2007	100,000.00	
Medtronic	Total 2007 Medtronic Payments				802,791.35
Merck	Breast Cancer and Supportive Care	CME	01/05/2007	281,674.05	
Merck	Herpes Zoster: Current and Emerging Solutions	CME	01/16/2007	8,900.00	
Merck	New Perspectives on Assessing Osteoporosis Risk and Insights Into Treatment Strategies	CME	03/14/2007	275,000.00	
Merck	Face Off with the Experts-Osteoporosis Case Challenge	CME	04/04/2007	300,000.00	
Merck	Osteoporosis in Practice: A Comprehensive Resource for Prevention and Treatment	CME	04/04/2007	210,000.00	
Merck	New Perspectives on Assessing Osteoporosis Risk and Insights Into Treatment Strategies	CME	04/17/2007	174,735.00	
Merck	Face Off with the Experts-Osteoporosis Case Challenge	CME	04/17/2007	40,000.00	
Merck	Osteoporosis in Practice: A Comprehensive Resource for Prevention and Treatment	CME	04/17/2007	40,000.00	
Merck	PONV Prophylaxis in At-risk OB/GYN Patients	CME	04/30/2007	249,900.00	
Merck	Total 2007 Merck Payments				1,580,209.05
Merck Schering Plough	Making the Case for Greater CHD Risk Reduction	CME	02/01/2007	150,049.20	

ROCKPOINTE, INC.
SCHEDULE OF PAYMENTS
01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
Merck Schering Plough	Making the Case for Greater CHD Risk Reduction	CME	03/27/2007	89,194.60	
Merck Schering Plough	Reaching Lipid Targets: Tougher Goals for Better Results	CME	07/23/2007	229,355.20	
Merck Schering Plough	Reaching Lipid Targets: Tougher Goals for Better Results	CME	11/20/2007	229,355.20	
Merck Schering Plough	Total 2007 Merck Schering Plough Payments				697,954.20
Novartis	Challenges of Managing OAB: Practical Information to Optimize Patient Outcomes	CME	11/05/2007	134,150.00	
Novartis	Control Hypertension: New Definitions, New Treatment Combinations and Models for Advances	CME	11/05/2007	478,938.00	
Novartis	Challenges of Managing OAB: Practical Information to Optimize Patient Outcomes	CME	11/07/2007	256,556.00	
Novartis	Total 2007 Novartis Payments				869,644.00
Pfizer	Smoking Cessation: An Integral Component to CVD Risk Reduction	CME	06/21/2007	197,810.00	
Pfizer	Differentiating Targeted Agents for Renal Cell Carcinoma	CME	08/06/2007	200,000.00	
Pfizer	Total 2007 Pfizer Payments				397,810.00
Pharmion	MDS In Focus	CME	01/30/2007	36,256.00	
Pharmion	Newly Diagnosed Multiple Myeloma in Young and Elderly Patients	CME	08/13/2007	57,621.50	
Pharmion	Newly Diagnosed Multiple Myeloma in Young and Elderly Patients	CME	09/13/2007	57,621.50	
Pharmion	MDS Diagnosis and Management: Understanding New Therapeutic Options	CME	09/19/2007	203,150.00	
Pharmion	Total 2007 Pharmion Payments				354,649.00
Sanofi Aventis	Evidence and Insights in the Treatment of Advanced Solid Tumors	CME	01/22/2007	770,323.25	
Sanofi Aventis	Advances in Treating Head and Neck Cancer	CME	03/21/2007	412,464.00	
Sanofi Aventis	Total 2007 Sanofi Aventis Payments				1,182,787.25
Schering Plough	A Fresh Look at Managing ACS Patients	CME	08/13/2007	114,066.40	
Schering Plough	Antiplatelet Treatment for ACS Patients: Weighing Long-Term Outcomes vs. Short-Term Risks	CME	08/13/2007	112,592.00	
Schering Plough	A Fresh Look at Managing ACS Patients	CME	09/20/2007	71,291.50	
Schering Plough	Antiplatelet Treatment for ACS Patients: Weighing Long-Term Outcomes vs. Short-Term Risks	CME	09/20/2007	70,370.00	
Schering Plough	Standards in Acute Coronary Syndromes: Guidelines for the Management of Patients with Unstable Disease	CME	11/08/2007	109,998.00	
Schering Plough	Antiplatelet Treatment for ACS Patients: Weighing Long-Term Outcomes vs. Short-Term Risks	CME	12/06/2007	70,370.00	
Schering Plough	A Fresh Look at Managing ACS Patients	CME	12/18/2007	71,291.50	
Schering Plough	Total 2007 Schering Plough Payments				619,979.40
Teva Neuroscience	Multiple Sclerosis Therapies: Unique Mechanisms of Action Update	CME	11/27/2007	103,020.00	
Teva Neuroscience	Total 2007 Teva Neuroscience Payments				103,020.00

ROCKPOINTE, INC.
SCHEDULE OF PAYMENTS
01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
Amylin-Lilly	Diabetes:From Guidelines to Clinical Practice	CME	10/13/2008	62,499.00	
Amylin-Lilly	Total 2008 Amylin-Lilly Payments				62,499.00
Astellas	Efficient Stroke Prevention: Therapeutic Strategies in Afib Patients	CME	11/05/2008	50,000.00	
Astellas	Bridging Treatment Gaps in Acute and Chronic Heart Failure	CME	11/12/2008	140,000.00	
Astellas	Total 2008 Astellas Payments				190,000.00
AstraZeneca	Managing LDL, Inflammation, and Atherosclerosis to Reduce CVD Risk	CME	07/14/2008	100,000.00	
AstraZeneca	Managing LDL, Inflammation, and Atherosclerosis to Reduce CVD Risk	CME	08/06/2008	100,000.00	
AstraZeneca	Managing LDL, Inflammation, and Atherosclerosis to Reduce CVD Risk	CME	10/06/2008	150,000.00	
AstraZeneca	Inflammatory Atherosclerotic Disease: Future Prospects for Intervention	CME	11/06/2008	100,000.00	
AstraZeneca	Total 2008 AstraZeneca Payments				450,000.00
Bristol-Myers-Squibb	Cardiac Surgery and Conjunctive Care	CME	05/05/2008	164,619.75	
Bristol-Myers-Squibb	Understanding The Role of Biologics for Optimal Management of RA: A Case Based Approach	CME	05/23/2008	260,660.25	
Bristol-Myers-Squibb	Adherence:The Silent CV Risk Factor	CME	08/14/2008	74,998.50	
Bristol-Myers-Squibb	Impact of Antiplatelet Therapy in Cardiac Surgery	CME	10/01/2008	142,462.50	
Bristol-Myers-Squibb	Diabetes:From Guidelines to Clinical Practice	CME	10/13/2008	46,874.25	
Bristol-Myers-Squibb	Adherence to Diabetic Treatment Regimens: Strategies for Improvement	CME	10/13/2008	74,999.25	
Bristol-Myers-Squibb	Achieving Strict Glucose Control in Type 2 Diabetes	CME	12/15/2008	194,606.75	
Bristol-Myers-Squibb	Management Strategies for Type 2 Diabetes:From Guidelines to Practice	CME	12/22/2008	282,691.50	
Bristol-Myers-Squibb	Total 2008 Bristol-Myers-Squibb Payments				1,241,912.75
Celgene Corporation	Clinical Challenges in MDS: Diagnosis & Managment for the Practicing Hematologists/Oncologist	CME	09/04/2008	50,000.00	
Celgene Corporation	Total 2008 Celgene Corporation Payments				50,000.00
Daiichi Sankyo	Post ACS & Post PCI Antiplatelet Therapy: Can We Better Protect Against Thromboembolic Events	CME	05/27/2008	249,998.00	
Daiichi Sankyo	Post ACS & Post PCI Antiplatelet Therapy: Can We Better Protect Against Thromboembolic Events	CME	08/20/2008	249,997.00	
Daiichi Sankyo	Total 2008 Daiichi Sankyo-Eli Lilly Payments				499,995.00
Eli Lilly	New Patient Care Data for STEMI	CME	01/07/2008	69,896.25	
Eli Lilly	Individualizing Therapy in Postmenopausal Osteoporosis	CME	03/24/2008	169,448.50	
Eli Lilly	Improving Outcomes in High-Risk Ovarian & Breast Cancer Patients	CME	04/03/2008	98,888.00	
Eli Lilly	Improving Outcomes in High-Risk Ovarian & Breast Cancer Patients	CME	05/15/2008	28,000.00	
Eli Lilly	Improving Outcomes in High-Risk Ovarian & Breast Cancer Patients	CME	05/27/2008	49,444.00	
Eli Lilly	Glucocorticoids & Osteoporosis: Practical Strategies to Improve Clinical Outcomes	CME	06/26/2008	139,460.00	
Eli Lilly	Individualizing Therapy in Postmenopausal Osteoporosis	CME	06/26/2008	84,724.25	
Eli Lilly	Improving Outcomes in High-Risk Ovarian & Breast Cancer Patients	CME	07/10/2008	49,444.00	
Eli Lilly	Individualizing Therapy in Postmenopausal Osteoporosis	CME	07/23/2008	84,724.25	
Eli Lilly	Glucocorticoids & Osteoporosis: Practical Strategies to Improve Clinical Outcomes	CME	12/10/2008	30,000.00	
Eli Lilly	Total 2008 Eli Lilly Payments				804,029.25
Genentech	Challenging Issues in the Management of Advanced Solid Tumors	CME	04/15/2008	174,025.84	
Genentech	Total 2008 Genentech Payments				174,025.84
Lantheus	A Sharper Image: Refocusing on Contrast Echocardiography	CME	10/01/2008	248,810.00	
Lantheus	Total 2008 Lantheus Payments				248,810.00
Medicare	Breakthrough Approaches to Protect Against Myocardial Ischemia/Reperfusion Injury	CME	05/08/2008	14,277.60	
Medicare	Total 2008 Medicare Payments				14,277.60
Medimmune	Respiratory Syncytial Virus: Strategies for Identification, Prevention & Management	CME	06/18/2008	108,783.68	
Medimmune	Addressing the Burden of Respiratory Syncytial Virus	CME	07/18/2008	40,381.00	

ROCKPOINTE, INC.
SCHEDULE OF PAYMENTS
01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
Medimmune	Respiratory Syncytial Virus: Strategies for Identification, Prevention & Management	CME	07/18/2008	78,309.75	
Medimmune	Respiratory Syncytial Virus: Strategies for Identification, Prevention & Management	CME	08/21/2008	108,783.68	
Medimmune	Addressing the Burden of Respiratory Syncytial Virus	CME	10/30/2008	40,381.00	
Medimmune	Respiratory Syncytial Virus: Strategies for Identification, Prevention & Management	CME	10/30/2008	78,309.75	
Medimmune	Total 2008 Medimmune Payments				454,948.86
Medtronic	Optimizing Treatment Strategies for Chronic Total Occlusions	CME	08/20/2008	73,995.00	
Medtronic	Acute and Chronic Care of Myocardial Infarction Patients	CME	08/27/2008	73,045.00	
Medtronic	Acute and Chronic Care of Myocardial Infarction Patients	CME	09/17/2008	96,681.00	
Medtronic	Issues and Controversies in PCI and Drug Eluting Stents	CME	10/13/2008	96,681.00	
Medtronic	Total 2008 Medtronic Payments				340,402.00
Merck	Optimizing Asthma Care	CME	04/28/2008	200,000.00	
Merck	Optimizing Asthma Care	CME	07/14/2008	93,970.00	
Merck	Diabetes:From Guidelines to Clinical Practice	CME	08/27/2008	275,000.00	
Merck	Total 2008 Merck Payments				568,970.00
Merck Schering Plough	Reaching Lipid Targets: Tougher Goals for Better Results	CME	01/07/2008	114,677.60	
Merck Schering Plough	Examining Surrogate Markers in Cardiovascular Clinical Trials	CME	09/15/2008	205,561.50	
Merck Schering Plough	Total 2008 Merck Schering Plough Payments				320,239.10
Novartis	Treating Hypertension to Reduce CV Risk	CME	03/10/2008	188,955.00	
Novartis	Adherence:The Silent CV Risk Factor	CME	03/10/2008	98,998.00	
Novartis	Blocking the Renin Angotension System	CME	03/24/2008	299,142.00	
Novartis	Total 2008 Novartis Payments				587,095.00
Otsuka	Restoring Balance: New Therapeutic Approaches to Acute Decomensated Heart Failure	CME	04/24/2008	259,992.00	
Otsuka	Bridging Treatment Gaps in Acute and Chronic Heart Failure	CME	12/22/2008	50,000.00	
Otsuka	Total 2008 Otsuka Payments				309,992.00
Pfizer	Challenging Issues in the Management of Advanced Solid Tumors	CME	07/10/2008	50,000.00	
Pfizer	Challenging Issues in the Management of Advanced Solid Tumors	CME	10/02/2008	50,000.00	
Pfizer	Challenging Issues in the Management of Advanced Solid Tumors	CME	11/13/2008	50,000.00	
Pfizer	Total 2008 Pfizer Payments				150,000.00
Schering Plough	Standards in Acute Coronary Syndromes: Guidelines for the Management of Patients with Unstable Disease	CME	01/07/2008	68,748.75	
Schering Plough	Antiplatelet Treatment for ACS Patients: Weighing Long-Term Outcomes vs. Short-Term Risks	CME	03/24/2008	466.99	
Schering Plough	Standards in Acute Coronary Syndromes: Guidelines for the Management of Patients with Unstable Disease	CME	03/24/2008	68,748.75	
Schering Plough	A Fresh Look at Managing ACS Patients	CME	03/31/2008	36,819.10	
Schering Plough	Four Tough Calls In Antithrombotics: Challenges of Incorporating Guidelines into Clinical Practice	CME	05/16/2008	128,947.00	
Schering Plough	Four Tough Calls In Antithrombotics: Challenges of Incorporating Guidelines into Clinical Practice	CME	11/20/2008	80,592.00	
Schering Plough	Total 2008 Schering Plough Payments				384,322.59
Solvay	Adherence:The Silent CV Risk Factor	CME	06/12/2008	99,998.00	
Solvay	Total 2008 Solvay Payments				99,998.00
TEVA Neuroscience, Inc.	Parkinson's Disease: Early Diagnosis and Preserving Quality of Life	CME	05/07/2008	46,987.10	
TEVA Neuroscience, Inc.	Total 2008 TEVA Payments				46,987.10
UCB	The Impact of Biologic Therapies in the Management of Crohn's Disease	CME	09/09/2008	199,710.00	
UCB	The Impact of Biologic Therapies in the Management of Crohn's Disease	CME	09/25/2008	99,854.00	
UCB	Total 2008 UCB Payments				299,564.00

ROCKPOINTE, INC.
SCHEDULE OF PAYMENTS
01-01-06 TO 06-30-09

Company	Program Title	Payment Description	Date of Payment	Amount	Yearly Total
Amgen	Clinical Cases in Osteoporosis	CME	03/17/2009	99,822.00	
Amgen	Preventing Osteoporotic Fractures: Recognizing and Managing Those at Risk	CME	06/26/2009	75,000.00	
Amgen	Total 2009 thru 06-30-09 Amgen Payments				174,822.00
AstraZeneca	Inflammatory Atherosclerotic Disease: Future Prospects for Intervention	CME	01/25/2009	222,598.00	
AstraZeneca	Inflammatory Atherosclerotic Disease: Future Prospects for Intervention	CME	02/03/2009	75,000.00	
AstraZeneca	Managing LDL, Inflammation, and Atherosclerosis to Reduce CVD Risk	CME	05/11/2009	47,247.00	
AstraZeneca	Total 2009 thru 06-30-09 Astrazeneca Payments				344,845.00
Boehringer Ingelheim	Emerging Therapeutic Opportunities in Antithrombotics & Anticoagulants	CME	03/25/2009	299,961.00	
Boehringer Ingelheim	Talking About Sex:Methods to Diagnose & Manage Female Sexual Disorders	CME	06/19/2009	247,505.00	
Boehringer Ingelheim	Total 2009 thru 06-30-09 Boehringer-Ingelheim Payments				547,466.00
Bristol-Myers-Squibb	Efficient Stroke Prevention: Therapeutic Strategies in Afib Patients	CME	01/21/2009	193,580.40	
Bristol-Myers-Squibb	The Impact of Antiplatelet Therapy in Cardiac Surgery	CME	03/16/2009	32,973.00	
Bristol-Myers-Squibb	Diabetes from Guidelines to Clinical Practice	CME	03/16/2009	15,042.00	
Bristol-Myers-Squibb	Understanding The Role of Biologics for Optimal Management of RA: A Case Based Approach	CME	03/30/2009	86,887.00	
Bristol-Myers-Squibb	Adherence:The Silent CV Risk Factor	CME	04/06/2009	24,500.00	
Bristol-Myers-Squibb	Total 2009 thru 06-30-09 Bristol-Myers-Squibb Payments				352,982.40
Daiichi Sankyo-Eli Lilly	Optimizing Antiplatelet Therapy in ACS: Balancing Efficacy & Safety in VA/NSTEMI	CME	06/18/2009	187,553.00	
Daiichi Sankyo-Eli Lilly	Total 2009 thru 06-30-09 Daiichi Sankyo-Eli Lilly Payments				187,553.00
Gilead	Understanding Stable Angina & Its Treatment & Emergent Therapeutic Approaches	CME	04/17/2009	84,200.00	
Gilead	Understanding Stable Angina & Its Treatment & Emergent Therapeutic Approaches	CME	06/24/2009	42,100.00	
Gilead	Total 2009 thru 06-30-09 Gilead Payments				126,300.00
Eiasi	Changing the Face of Chemotherapy Induced Nausea and Vomiting	CME	05/06/2009	244,680.00	
Eiasi	Total 2009 thru 06-30-09 Eisai Payments				244,680.00
Eli Lilly	Preventing Osteoporotic Fractures: Recognizing & Managing Those at Risk	CME	04/13/2009	75,204.00	
Eli Lilly	Translating Research into Individualized Therapy in NSCLC: The Impact of Predictive Factors	CME	05/15/2009	159,048.00	
Eli Lilly	Total 2009 thru 06-30-09 Eli Lilly Payments				234,252.00
Medimmune	Addressing the Burden of Respiratory Syncytial Virus	CME	01/05/2009	118,690.75	
Medimmune	Respiratory Syncytial Virus: Strategies for Identification, Prevention & Management	CME	01/16/2009	108,783.66	
Medimmune	Addressing the Burden of Respiratory Syncytial Virus	CME	05/29/2009	114,688.75	
Medimmune	Total 2009 thru 06-30-09 Medimmune Payments				342,163.16
Merck	Control Asthma Now: Pharmacologic Strategies to Improve Asthma Control	CME	04/30/2009	150,000.00	
Merck	Total 2009 thru 06-30-09 Merck Payments				150,000.00
Merck Schering Plough	Examining Surrrogate Markers in Cardiovascular Clinical Trials	CME	01/05/2009	205,581.50	
Merck Schering Plough	Total 2009 thru 06-30-09 Merck Schering Plough Payments				205,581.50
Otsuka	New Thinking on the Pathogenic & Prognostic Implications of Hyponatremia in Heart Failure	CME	04/20/2009	208,555.00	
Otsuka	Total 2009 thru 06-30-09 Otsuka Payments				208,555.00
Schering Plough	Four Tough Calls In Antithrombotics: Challenges of Incorporating Guidelines into Clinical Practice	CME	01/12/2009	80,592.00	
Schering Plough	Four Tough Calls In Antithrombotics: Challenges of Incorporating Guidelines into Clinical Practice	CME	04/16/2009	32,236.75	
Schering Plough	Total 2009 thru 06-30-09 Schering Plough Payments				112,828.75
St. Jude Medical	Bridging Treatment Gaps in Acute and Chronic Heart Failure	CME	02/17/2009	5,000.00	
St. Jude Medical	Total 2009 thru 06-30-09 St. Jude Medical Payments				5,000.00